Clarus Therapeutics Holdings, Inc. Warrants
CRXTW
CRXTW was delisted on the 30th of August, 2022.
5 hedge funds and large institutions have $1K invested in Clarus Therapeutics Holdings, Inc. Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 13 closing their positions.
72% less funds holding
Funds holding: 18 → 5 (-13)
99% less capital invested
Capital invested by funds: $192K → $1K (-$191K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 13
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$88K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$20K |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$17K |
| 4 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$13K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$10K |
CRXTW Hedge Fund Activity: Q3 2022 in Review
5 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) for Q3 2022, worth a combined $1K — down 99% from $192K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CRXTW and 0 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was LMR Partners, exiting entirely with an estimated $88K sold.
- 5 institutional investors held Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) as of Q3 2022, down from 18 in Q2 2022.
- Funds reported $1K of Clarus Therapeutics Holdings, Inc. Warrants stock for Q3 2022, down 99% quarter-over-quarter.
- 0 funds opened new Clarus Therapeutics Holdings, Inc. Warrants positions in Q3 2022 and 13 closed out, a net change of -13 holders.
- The largest Clarus Therapeutics Holdings, Inc. Warrants seller in Q3 2022 was LMR Partners, an estimated $88K sold.
Based on aggregated 13F filings for Q3 2022.